On March 12, the FDA approved an expanded age indication for AREXVY to include adults aged 18-49 years at increased risk for RSV-LRTD. The FDA also added a limitation of use that AREXVY is not for use in pregnant individuals. Log in to read the...
Sanofi invites you to attend this complimentary 60-minute webinar on coding, coverage, and reimbursement for Flublok® (Influenza Vaccine), Fluzone® High-Dose (Influenza Vaccine), Fluzone® (Influenza Vaccine), Beyfortus® (nirsevimab-alip) and Nuvaxovid™ (COVID-19 Vaccine, Adjuvanted). There are 6 live sessions for members to choose from, each including a presentation...
AbbVie announced that the 2026 Wholesale Acquisition Cost of the Liletta IUD has increased as of January 1st. However, there will be no price increase for PAA members until April 1, 2026. PAA members can order Liletta at the current contract price until March 31,...
GSK has announced that PAA vaccine contract pricing will change effective 2/1/2026. Also as GSK transitions to Shingrix prefilled syringes on 2/2/2026, they have provided the important information for members regarding availability. Log in to the member website to access the details. Not a member? Join today. ...
Sanofi and Pfizer have announced that PAA vaccine contract pricing will change effective 1/1/2026. Members can log in to view the price changes....
Practices who have qualified to receive a rebate from Physicians' Alliance of America based on their GSK vaccine purchases will soon be receiving a check. If your practice qualified for this PAA rebate, please be on the lookout for an envelope featuring our Vaccine Rebate logo. The PAA Vaccine...
We are excited to announce major improvements to our Vaccine Rebate Program! We are increasing our members’ rebate potential and decreasing the thresholds to qualify. Sign in to our member site to view details. The PAA Vaccine Rebate Program has sent more than $20 million to our...
Pfizer invites you to attend an informative webinar that will provide an overview of billing and coding information for ABRYSVO maternal RSV vaccination, including relevant codes, documentation requirements, and reimbursement information. This session will include reimbursement and coding examples to help prepare for the upcoming...
Learn about compelling data for infant RSV immunization to support your immunization efforts for the 2025–2026 RSV season. Sanofi invites you to attend this session which will focus on Beyfortus® (nirsevimab-alip) 50mg and 100mg and how to effectively implement it in your practice. Topics include: • Highlight the...
GSK announces an expanded indication for Arexvy, and invites PAA members to register for their RSV Awareness Webinar Series, The Risk of Respiratory Syncytial Virus (RSV): Disease Burden and Vaccination. Log in to learn more and to register....
